Abstract Library

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,

#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Vitali E, Cambiaghi V, Loiarro F, Zerbi A, Colombo P,

Keywords: FLNA, SST2, GEP-NET,

#416 A Rare Case of Cushing Syndrome Caused by an Ectopic ACTH-Secreting Pancreatic Neuroendocrine Tumor in a Patient with Von Hipple-Lindau Disease

Introduction: Von Hipple-Lindau (VHL) disease is a rare autosomal dominant disorder, that causes the susceptibility to various tumors, both benign and malignant. The most frequent tumors are central nervous system haemangioblastomas, especially cerebellum and retinal haemangioblastomas, renal cell carcinoma /renal cysts and pheocromocytoma.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sburlati L, Ridolfi C, Gavazzi F, Colombo P, Brunetta E,

Keywords: von Hipple-Lindau disease, Cushing syndrome ,